At a glance
ClinicalIndex Comparison RecordN/ACompleted· 189,629 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post-licensure Surveillance Program for the Safety of GARDASIL™ in a Managed Care Organization Setting
In Brief
An observational study for Human Papillomavirus Infection. Completed, enrolled 189,629 participants.
Detailed Summary
This is a post-licensure safety surveillance program to detect potential safety signals in subjects, from the managed care organizations database, who have used GARDASIL™.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Papillomavirus Infection
Countries--
CollaboratorsKaiser Permanente
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedMar 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedMar 2, 2010
Enrollment StartFeb 6, 2007
Primary CompletionDec 13, 2010
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.3 years ago